Richtlijn: Niet-kleincellig longcarcinoom (2.0) - Kwaliteitskoepel

Richtlijn: Niet-kleincellig longcarcinoom (2.0)105 - Costa DBCosta DB, Kobayashi S, Tenen DG, et al: Pooled analysis of the prospective trials of gefitinib monotherapyfor EGFR-mutant non-small cell lung cancers. Lung Cancer 58:95-103, 2007.106 - Coughlin MCoughlin M, Deslauriers J, Beaulieu M, Fournier B, Piraux M, Rouleau J, et al. Role of mediastinoscopy inpre-treatment staging of patiënts with primary lung cancer. Ann Thorac Surg 40:556-560 1985.107 - Cox JDCox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomised phase I-II trial ofhyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with >69.6 Gy in favourable patiënts with radiation therapy oncology group stage III non-small cell lungcarcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:543-555, 1990.108 - Cox JDCox JD. Patterns of failure followingg treatment of apparently localized carcinoma of the lung. In: MuggiaFM Rozencwieg M (eds). Lung cancer; progress in therapeutic research. Vol 11. New York: Raven,279-328, 1979.109 - Cox KCox K, Wilson E, Heath L, Collier J, Jones L, Johnston I. Preferences for follow-up after treatment for lungcancer: Assessing the nurse-led option. Cancer Nursing 2006, vol 29, no3, 176-187.111 - Crabtree TDCrabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, Kreisel D, Patterson GA, BradleyJD. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. JThorac Cardiovasc Surg 140:377-386, 2010.112 - Cullen MHCullen MH, Zatloukal P, Sorenson S, et al: A randomized phase III trial comparing standard and high-dosepemetrexed as second-line treatment in patiënts with locally advanced or metastatic nonsmall-cell lungcancer. Ann Oncol 19:939-945, 2008.113 - Curran WJCurran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison ofsequential vs concomitant chemo-radiation for patiënts with unresected stage III NSCLC: RTOG 9410.Proc Am Soc Clin Oncol 22: 621-621, 2003.114 - Cybulsky IJCybulsky IJ, Bennet WF. Mediastinoscopy as a routine outpatiënt procedure. Ann Thorac Surg 58:176-178,1994.115 - D’Addario GD’Addario G,Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy inadvanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol2005;23:2926-2936.116 - Dahabreh IJDahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation andgene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lungcancer. Clin. Cancer Res 16:291-303, 2010.117 - Dahabreh JDahabreh J, Linerdou H, Kosmidis P, Bafaloukos D, Murray S. EGFR gene copy number as a predictivebiomarker for patiënts receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysisin non-small-cell lung cancer. Ann of Oncol sept 8, 2010.118 - Dahse RDahse R, Driemel O, Schwarz S, et al. Epidermal growth factor receptor kinase domain mutations are rare06/09/2011 Niet-kleincellig longcarcinoom (2.0) 101